Polymer-supported crown-ethers 9 and 11 (4.5-62% ring substitution) have been obtained by the reaction of 1% crosslinked chloromethylated polystyrenes with (hydroxymethyl) and (ω-hydroxynonyl)-18-crown-6, respectively. (Hydroxymethyl) and (ω-hydroxynonyl) [2.2.2] cryptands have also been prepared and linked in a similar way to afford catalysts 10 and 12 (3-6% ring substitution). Condensation of (aminomethyl) and (ω-aminodecyl [2.2.2] crypands with carboxylated 1% crosslinked polystyrene gave catalysts 13 and 14 (5-20% ring substitution). Phase-transfer catalytic activity of polymer-supported crown-ethers and cryptands has been tested in anion promoted nucleophilic aliphatic substitutions, and compared with that of polymer-supported phosphonium salts. The results indicate that catalytic activity of crown-ethers strongly depends on the combination of three parameters: the nature of the nucleophile, the percent ring substitution, and the presence of a spacer chain. Catalytic activity of cryptands is higher than that of crown-ethers and quaternary salts with similar percent ring substitution. It is much less dependent on the nature of the anions and on the presence of a spacer chain. As for the related quaternary salts, phase-transfer reactions promoted by polymer-supported crown-ethers and cryptands follow a mechanism identical with that observed for soluble catalysts: the reactions occur in the organic shell surrounding a complexed ligand; anions are exchanged at the water-organic solvent interface, the exchange not requiring the concomitant transfer of cationic counterparts.
No takes yet. Share an insight, caveat, or question.
Montanari et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: